Ovarian cancer: identifying and managing familial and genetic risk-summary of new NICE guidance

BMJ. 2024 May 9:385:q807. doi: 10.1136/bmj.q807.

Authors

Eric Slade¹, Laura Berg², Katharina Dworzynski², Ranjit Manchanda^{3

4

5}; Guideline Committee

Collaborators

Guideline Committee:
Victoria Barber, Rebecca Bowen, Adam Brentnall, Alison L Cameron, D Mark Davies, Melanie C Davies, D Gareth Evans, Judith Hayward, R Manchanda, W Glenn McCluggage, Tracie Miles, Kevin Monahan, Davina Moses, Fiona Robb, Adam N Rosenthal, Lucy Side, Joanne Stanford, Britta Stordal, Vishakha Tripathi

Affiliations

¹ National Institute for Health and Care Excellence, London eric.slade@nice.org.uk r.manchanda@qmul.ac.uk.
² National Institute for Health and Care Excellence, London.
³ Wolfson Institute of Population Health, Queen Mary University of London eric.slade@nice.org.uk r.manchanda@qmul.ac.uk.
⁴ Barts Health NHS Trust, Royal London Hospital.
⁵ Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine.

PMID: 38724099
DOI: 10.1136/bmj.q807

No abstract available

MeSH terms

Female
Genetic Predisposition to Disease*
Genetic Testing
Humans
Ovarian Neoplasms* / diagnosis
Ovarian Neoplasms* / genetics
Ovarian Neoplasms* / therapy
Practice Guidelines as Topic
Risk Assessment
Risk Factors
United Kingdom